Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer
Phase 1 Terminated
6 enrolled 11 charts
Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors
Phase 1 Completed
260 enrolled 52 charts
ABEMA Alone or in COMBO With MK-6482
Phase 1 Completed
11 enrolled 9 charts
TIL Therapy for Metastatic Renal Cell Carcinoma
Phase 1 Completed
5 enrolled 8 charts
Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors
Phase 1 Terminated
37 enrolled 32 charts
APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma
Phase 1 Completed
42 enrolled 17 charts
PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors
Phase 1 Terminated
49 enrolled 33 charts
Study of ADCT-301 in Patients With Selected Advanced Solid Tumors
Phase 1 Terminated
78 enrolled 39 charts
Study of PF-07263689 in Participants With Selected Advanced Solid Tumors
Phase 1 Terminated
13 enrolled 16 charts
A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer
Phase 1 Completed
52 enrolled 21 charts
Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma
Phase 1 Completed
14 enrolled 13 charts
Study of Safety and Functional Imaging of cG250 and Sunitinib in Patients With Advanced Renal Cell Carcinoma
Phase 1 Terminated
8 enrolled 18 charts
A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab
Phase 1 Completed
104 enrolled 23 charts
Treatment of Patients With Advanced Renal Cancer With a Radiolabeled Antibody, Yttrium-90 Conjugated Chimeric G250
Phase 1 Completed
18 enrolled 15 charts
Safety Study With the Antibody, cG250, and Isotope, 124-Iodine, to Diagnose Patients With Renal Masses.
Phase 1 Completed
26 enrolled 11 charts
Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566
Phase 1 Completed
174 enrolled 68 charts
M8891
Phase 1 Terminated
27 enrolled 26 charts
FPA008-003
Phase 1 Completed
313 enrolled 30 charts
JAVELIN Renal 100
Phase 1 Completed
55 enrolled 27 charts
MDX1106-03
Phase 1 Completed
395 enrolled 22 charts
Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016)
Phase 1 Completed
194 enrolled 18 charts
Phase I Biomarker Study (BMS-936558)
Phase 1 Completed
119 enrolled 20 charts
A Dose Finding Study To Evaluate Safety, Drug Interaction, Tumor Markers Of Axitinib In Combination With MK-3475 In Adult Patients With Previously Untreated Advanced Renal Cell Cancer
Phase 1 Completed
52 enrolled 27 charts
MK-3475-031
Phase 1 Terminated
10 enrolled 13 charts
Study of the Pan-DAC Inhibitor AR-42 and Pazopanib in Advanced Sarcoma and Kidney Cancer
Phase 1 Terminated
6 enrolled 12 charts
Study of Lenvatinib in Combination With Everolimus in Participants With Unresectable Advanced or Metastatic Renal Cell Carcinoma (RCC)
Phase 1 Completed
7 enrolled 17 charts
A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors
Phase 1 Terminated
29 enrolled 19 charts
A Phase 1b Trial in Patients With Renal Cell Cancer
Phase 1 Completed
21 enrolled 10 charts
A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883, MK-7454-006)
Phase 1 Terminated
4 enrolled 8 charts
Sunitinib for Metastatic Renal Cell Cancer With Imaging Biomarker Assessments for the Early Prediction of Tumor Response
Phase 1 Completed
25 enrolled 7 charts
PEG-Interferon Alfa-2b and Sorafenib in Treating Patients With Unresectable or Metastatic Kidney Cancer
Phase 1 Terminated
1 enrolled 2 charts
A Study of V934/V935 Vaccine in Cancer Participants With Selected Solid Tumors (V934-002)
Phase 1 Completed
37 enrolled 10 charts
MDX1106-01
Phase 1 Completed
39 enrolled 28 charts
Safety and Efficacy Study of ALT-801 to Treat Progressive Metastatic Malignancies
Phase 1 Completed
26 enrolled 13 charts